Sir
In a recent letter to the editor, Shamash et al (2000) argued that a raised serum lactate dehydrogenase catalytic concentration (S-LD) prior to induction chemotherapy for patients with germ cell tumours predicted a poor outcome. They referred to increasing evidence for a raised S-LD before first-line chemotherapy being as good if not better than serum human chorionic gonadotropin concentration (ShCG), as found in, e.g., International Germ Cell Cancer Collaboratory Group (IGCCCG) (von Eyben et al, 1983; Mead and Stenning, 1997) . Correspondingly, the fifth edition of the TNM (T = primary tumour, N = lymph node, M = distant metastases) classification included S-LD, serum alpha fetoprotein concentration, and ShCG as serum tumour markers for testicular germ cell tumours (TGCT) (Sobin and Wittekind, 1997) . The TNM classification is well documented and has been validated repeatedly. LD consists of five LD isoenzymes. The literature points to a characteristic S-LD isoenzyme pattern in patients with TGCT and a raised S-LD: they predominantly have a raised S-LD isoenzyme 1 catalytic concentration (S-LD-1) (von Eyben et al, 1983) . In contrast, patients with a raised S-LD due predominantly to S-LD isoenzyme 5 catalytic concentration most likely have presence of another disease, not TGCT. The S-LD-1 pattern in patients with TGCT reflects a characteristic chromosomal abnormality in the tumours: a high copy number of the short arms of chromosome 12, 12p, often with an isochromosome of 12p, i(l2p) (von Eyben et al, 1992a) .
We combined the results of two published series of patients with metastatic TGCT monitored with S-LD-1 in Table 1 ( von Eyben et al, 1992b; . Even though the patients were treated at two institutions using different staging systems and treatments, the two series showed consistent findings. 42 of 81 patients (52%) had a raised S-LD-1 and 41 of the 42 also had a raised S-LD. However, eight patients had a discordant pattern with a normal S-LD-1 and a raised S-LD (Figure 1 ). Separated in three subgroups according to the S-LD-1 level, the 81 patients differed markedly regarding the survival (P < 0.00001, log-rank test, chi square for trend) (Figure 2A ). Overall S-LD, S-hCG, and the prognostic classification of the IGCCCG study also predicted the survival (P = 0.00032, 0.02, and 0.0005, respectively, Figure 2B and 2C) whereas S-AFP did not (P = 0.68) ( Figure 2D ). The subgroup of 39 patients with a normal S-LD-1 had the best survival and this favourable survival was not influenced whether S-LD was normal (31 patients) or raised (eight patients) (P = 0.56) ( Figure 2E ). Eight patients with an S-LD-1/S-LD fraction > 0.375 had a poorer survival than the 73 with a lower fraction (P = 0.002) ( Figure 2F ). So S-LD-1 might add prognostic information even for the TGCT patients with a raised S-LD. In one of the series, S-LD isoenzyme 5 catalytic concentration did not have a prognostic significance (von Eyben et al, 2000) . Accordingly, the prognostic implication of a raised S-LD might be solely due to a raised S-LD-1.
S-LD-1 gave a larger difference in survival between the subgroups of patients with the best and the poorest survival than the IGCCCG classification. So the TNM classification for patients with TGCT may not be the optimum usage of the available prognostic information.
These observations indicate that S-LD-1 is better than S-LD to predict the survival of patients with TGCT. However, the findings should be validated in larger series of patients with TGCT. We welcome interested oncologists to participate in a multicentre study of this question. Serum lactate dehydrogenase isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours -reply Sir von Eyben et al describe their experience of splitting total LDH into its various isoenzymes and have identified LDH isoenzyme 1 (S-LD-1) as having prognostic significance in untreated patients with metastatic germ cell tumours. The evidence they present is clearly impressive and S-LD-1 appears to be able to identify patients with a poor outcome as effectively as the IGCCCG specification or serum HCG alone.
